Lung Cancer Publications

 

Selected Publications: Jun - Dec 2016

 

  1. Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. Onco Targets Ther. 2016 May 30. 9:3187-95. Ang YL, Lim JS, Soo RA.
  2. Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. Nat Commun. 2016 Jun 21; 7:11702. Zhang WC, Chin TM, Yang H, Nga ME, Lunny DP, Lim EK, Sun LL, Pang YH, Leow YN, Malusay SR, Lim PX, Lee JZ, Tan BJ, Shyh-Chang N, Lim EH, Lim WT, Tan DS, Tan EH, Tai BC, Soo RA, Tam WL, Lim B.
  3. Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression. Sci Transl Med. 2016 Aug 3; 8(350): 350ra104. Yong KJ, ... Soo RA, ... Levantini E et al.
  4. Targeting SALL4 by entinostat in lung cancer. Oncotarget. 2016 Sep 26. Yong KJ, Li A, Ou WB, Hong CK, Zhao W, Wang F, Tatetsu H, Yan B, Qi L, Fletcher JA, Yang H, Soo RA, Tenen DG, Chai L.
  5. Quantitative Accuracy and Lesion Detectability of Low-Dose FDG-PET for Lung Cancer Screening. J Nucl Med. 2016 Sep 29. Schaefferkoetter JD, Yan J, Soderlund TA, Townsend DW, Conti M, Tam JKSoo RATham I.
  6. A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation. Cancer Lett. 2016 Oct 10; 381(1):49-57. Ong PS, Wang L, Chia DM, Seah JY, Kong LR, Thuya WL, Chinnathambi A, Lau JY, Wong ALYong WP, Yang D, Ho PC, Sethi G, Goh BC.
  7. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence. Ther Adv Respir Dis. 2016 Oct; 10(5):444-54. Lim JS, Soo RA.
  8. The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients. 2016 Nov; Thongprasert S, Yang PC, Lee JS, Soo RA, Gruselle O, Myo A, Louahed J, Lehmann FF, Brichard VG, Coche T.